convent
monoclon
antibodi
mab
wide
use
research
diagnost
applic
due
high
affin
specif
howev
multipl
limit
larg
size
complex
structur
sensit
extrem
ambient
temperatur
potenti
weaken
perform
mab
certain
applic
address
problem
explor
new
antigen
binder
extens
requir
relat
improv
qualiti
current
diagnost
platform
recent
year
new
immunoglobulinbas
protein
name
variabl
domain
new
antigen
receptor
vnar
discov
shark
unlik
convent
mab
sever
advantag
vnar
includ
small
size
better
thermost
peculiar
paratop
structur
attract
interest
research
explor
articl
aim
first
present
overview
shark
vnar
outlin
characterist
outstand
new
reagent
diagnost
therapeut
applic
antibodi
power
tool
research
diagnost
due
high
affin
specif
toward
target
antigen
nowaday
monoclon
antibodi
mab
wide
use
detect
biomark
deriv
variou
pathogen
diseas
variou
immunoassay
platform
unlik
polyclon
antibodi
pab
monospecif
higher
puriti
mab
enabl
perform
multipl
applic
includ
evalu
chang
molecular
conform
target
proteinprotein
interact
identifi
singl
member
protein
famili
term
structur
antibodi
also
known
immunoglobulin
ig
structur
complex
larg
heterotetramer
protein
compos
two
heavi
chain
two
light
chain
fig
heavi
chain
convent
igg
consist
three
constant
domain
variabl
domain
vh
wherea
light
chain
consist
constant
domain
cl
variabl
domain
vl
howev
efficaci
mab
could
limit
larg
molecular
size
kda
structur
complex
paratop
may
capabl
access
certain
antigen
cryptic
epitop
result
poor
bind
affin
degener
mab
high
temperatur
humid
main
factor
affect
sensit
could
simpli
lead
fals
posit
result
rdt
although
mani
rdt
devic
kept
well
seal
plastic
packet
overcom
humid
exposur
high
ambient
temperatur
alway
lead
deviat
rdt
perform
ensur
optimum
perform
rdt
field
rdt
devic
recommend
store
ambient
unfortun
provis
refriger
storag
system
maintain
optimum
perform
rdt
alway
problem
mani
lowresourc
region
electr
suppli
avail
overcom
circumst
explor
new
antigen
binder
natur
heatstabl
extens
need
improv
current
diagnost
platform
earli
camelid
shark
discov
possess
unconvent
antibodi
immun
system
known
camelid
heavychain
antibodi
hcab
immunoglobulin
new
antigen
receptor
ignar
respect
subsequ
recognit
shown
variabl
domain
antibodi
camelid
vhh
shark
vnar
contain
autonom
function
singledomain
antibodi
owe
rel
small
size
high
specif
cognat
antigen
high
physiochem
stabil
natur
occur
antibodi
domain
consid
promis
candid
biomed
develop
unlik
convent
antibodi
flat
concav
antigenbind
site
wide
varieti
loop
length
structur
present
vhh
vnar
made
capabl
access
cryptic
epitop
catalyt
cleft
enzym
first
vhhbase
drug
antiywf
caplacizumab
alreadi
approv
current
progress
vnar
may
substanti
render
new
percept
attitud
toward
molecul
medic
scientif
commun
henc
articl
aim
review
uniqu
characterist
shark
vnar
discuss
potenti
use
shark
vnar
diagnost
well
therapeut
platform
class
natur
heavychain
antibodi
known
immunoglobulin
new
antigen
receptor
ignar
discov
cartilagin
fish
flajnik
cowork
ignar
uniqu
unconvent
antibodi
identifi
sever
differ
type
shark
includ
nurs
shark
ginglymostoma
cirratum
wobbegong
shark
orectolobu
maculatu
smooth
dogfish
mustelu
cani
band
houndshark
triakiss
cyllium
horn
shark
heterodontu
francisci
studi
also
shown
ignar
play
pivot
role
adapt
immun
system
cartilagin
anim
immunomicroscop
techniqu
exhibit
ignar
share
structur
homolog
tcell
receptor
variabl
region
antibodi
vl
chain
cell
adhes
molecul
henc
abil
demonstr
possibl
common
ancestr
receptor
molecul
ignar
postul
evolv
recruit
immun
system
function
antibodylik
structur
shown
fig
ignar
exist
homodim
natur
devoid
light
chain
chain
ignar
consist
five
constant
domain
follow
one
variabl
domain
variabl
domain
ignar
refer
vnar
contain
two
complementaritydetermin
region
cdr
known
unlik
convent
igg
shark
vnar
undergon
evolut
compens
therefor
allow
divers
vnar
achiev
long
variabl
protrud
addit
divers
evid
connect
two
hypervari
region
hv
moreov
peculiar
structur
combin
support
intermolecular
disulphid
bridg
confer
vnar
form
special
paratop
access
confin
epitop
owe
absenc
vnar
thu
far
smallest
natur
occur
immunoglobulinbas
protein
scaffold
molecular
mass
kda
anim
kingdom
presenc
cystein
residu
simpl
singl
chain
structur
vnar
afford
remark
refold
properti
exposur
temperatur
make
prefer
diagnost
applic
heat
may
tempor
occur
vnar
famili
categor
four
type
fig
base
posit
number
noncanon
cystein
residu
type
vnar
possess
two
pair
cystein
residu
extra
cystein
residu
framework
base
crystal
structur
analysi
noncanon
cystein
residu
occur
framework
type
vnar
form
disulphid
bond
cystein
residu
caus
loop
held
tightli
toward
region
far
type
vnar
found
nurs
shark
ginglymostoma
cirratum
may
uniqu
speci
type
ii
vnar
cystein
residu
identifi
respect
form
disulphid
bond
bring
loop
close
proxim
nonetheless
lack
cystein
motif
anchor
framework
region
caus
form
protrus
structur
make
capabl
target
groov
exampl
activ
site
enzym
due
strong
select
pressur
two
cystein
residu
type
vnar
associ
framework
counterpart
type
vnar
longer
compar
type
ii
vnar
averag
residu
respect
howev
type
ii
vnar
commonli
identifi
shark
speci
till
recent
type
iii
vnar
predominantli
express
newborn
shark
view
amino
acid
content
type
iii
vnar
similar
type
ii
vnar
addit
conserv
tryptophan
residu
howev
type
iii
vnar
possess
shorter
lack
sequenc
divers
may
partli
due
region
shark
gene
fuse
vgene
type
iii
hypothes
type
iii
vnar
evolv
protect
newborn
shark
earli
stage
exposur
common
pathogen
may
involv
develop
immun
system
adult
shark
isotyp
quickli
overtaken
matur
class
vnar
lastli
type
iv
vnar
sometim
refer
type
iib
lack
noncanon
disulphid
bond
found
type
vnar
thu
topolog
antigenbind
site
type
iv
vnar
flexibl
moreov
type
iv
vnar
invari
tryptophan
residu
identifi
refer
type
iiib
natur
scaffold
ignar
vhvl
combinatori
diversif
devoid
light
chain
howev
diversif
process
gener
occur
convent
antibodi
replac
uncommon
diversif
process
region
higher
mammal
antibodi
gene
gener
arrang
transloconorgan
wherea
shark
found
clusterorgan
cluster
arrang
cluster
consist
one
v
segment
one
segment
one
j
segment
one
c
segment
singl
set
c
segment
arrang
exclus
activ
rag
recombinas
within
individu
cluster
heterogen
shark
ignar
repertoir
expand
extens
junction
diversif
nregion
addit
pnucleotid
addit
trim
dregion
rearrang
shark
contain
convent
germin
centr
found
mammalian
immunoglobulin
nonetheless
initi
combinatori
divers
primarili
limit
extend
somat
hypermut
antigendriven
manner
mutat
cluster
cdr
mutat
pattern
frequenc
process
similar
mammalian
antibodi
bia
transit
transvers
mechan
favour
serin
codon
agct
hotspot
mutat
major
chang
base
replac
usual
occur
tandem
especi
mutat
hotspot
palindrom
repeat
flajnik
colleagu
report
somat
hypermut
promot
gradual
increas
affin
occur
immun
result
affin
matur
vivo
show
prone
somat
mutat
may
involv
antigen
bind
mutat
also
favour
type
type
ii
therefor
postul
mutat
could
either
directli
contribut
antigen
bind
chang
stabil
conform
antigen
bind
targetspecif
vnar
isol
rang
shark
speci
includ
nurs
shark
ginglymostoma
cirratum
wobbegong
shark
orectolobu
maculatu
spini
dogfish
squalu
acanthia
smooth
dogfish
mustelu
cani
isol
targetspecif
clone
sever
display
technolog
phage
display
ribosom
display
yeast
display
perform
elsewher
approach
phage
display
technolog
popular
wide
employ
isol
shark
vnar
target
antigen
technolog
allow
phage
phenotyp
genotyp
physic
link
wherebi
display
peptid
protein
express
fusion
phage
coat
protein
undergo
screen
process
known
biopan
techniqu
gene
encod
antibodi
bind
domain
fuse
bacteriophag
coat
protein
gene
result
antibodi
display
surfac
bacteriophag
select
antigenrecogn
binder
principl
phage
display
technolog
illustr
fig
order
isol
targetspecif
antibodi
use
display
technolog
construct
appropri
antibodi
librari
mandatori
thu
far
sever
type
vnar
librari
gener
includ
immun
librari
librari
synthet
librari
semisynthet
librari
nuttal
colleagu
construct
semisynthet
vnar
librari
use
natur
framework
isol
wobbegong
shark
orectolobu
maculatu
studi
employ
random
mutagenesi
region
success
isol
recombin
vnar
specif
gingipain
k
proteas
porphyromona
gingivali
extend
studi
increas
librari
size
introduct
natur
occur
vnar
shark
repertoir
surprisingli
two
natur
occur
vnar
protein
deriv
synthet
vnar
librari
isol
liu
cowork
success
isol
vnar
target
cholera
toxin
staphylococc
enterotoxin
b
seb
ricin
botulinum
toxin
bonta
complex
toxoid
semisynthet
librari
made
spini
dogfish
squalu
acanthia
targetspecif
vnar
impress
affin
also
isol
mani
differ
target
immun
recent
leow
colleagu
success
isol
sever
uniqu
vnar
clone
specif
malaria
biomark
wobbegong
shark
orectolobu
maculatu
immun
variou
method
use
construct
antibodi
phage
display
librari
common
method
pcr
amplif
antibodi
gene
follow
enzymat
digest
ligat
phagemid
vector
howev
method
time
consum
may
experi
low
effici
ligat
transform
step
henc
group
research
develop
librari
construct
method
base
pcr
extens
assembl
follow
selflig
easel
significantli
shorten
time
need
construct
librari
use
method
larg
highli
divers
vnar
librari
deriv
six
nurs
shark
ginglymostoma
cirratum
librari
size
recent
gener
nurs
shark
vnar
librari
panel
vnar
binder
specif
cancer
therapyrel
antigen
human
epiderm
growth
factor
receptor
program
cell
isol
meanwhil
vnar
specif
viral
antigen
middl
east
respiratori
syndrom
mer
sever
acut
respiratori
syndrom
sar
spike
protein
also
isol
recent
therefor
find
obtain
herein
convinc
vnar
clone
select
nurs
shark
vnar
librari
may
potenti
develop
therapeut
antibodi
human
process
undertaken
applic
shark
vnar
extens
studi
recent
year
addit
immunodiagnost
applic
potenti
vnar
develop
reagent
immunotherapeut
applic
well
studi
elsewher
follow
section
develop
vnar
variou
applic
discuss
fig
principl
phage
display
technolog
firstli
librari
antibodi
gene
clone
phagemid
vector
phage
display
librari
obtain
transform
escherichia
coli
recombin
phagemid
rescu
phage
helper
phage
phage
display
librari
subject
sever
round
affin
select
biopan
isol
target
specif
binder
involv
bind
wash
elut
infect
amplif
lastli
isol
clone
screen
elisa
assay
follow
dna
sequenc
applic
vnar
biomark
variou
diseas
summar
tabl
vnar
isol
nuttal
colleagu
demonstr
high
affin
toward
p
falciparum
apic
membran
antigen
via
uniqu
undergo
affin
matur
merozoit
surfac
protein
importantli
use
erythrocyt
penetr
malaria
parasit
report
bind
specif
vnar
monoval
clone
toward
compar
rang
commerci
antibodi
reagent
griffith
colleagu
demonstr
thermost
isol
vnar
superior
convent
mab
target
variou
format
refold
abil
vnar
retain
despit
temperatur
rais
furthermor
vnar
proven
long
shelflif
incub
ambient
temperatur
month
without
lose
bind
function
addit
liu
colleagu
examin
melt
temperatur
refold
capabl
vnar
use
fluorescencebas
melt
assay
circular
dichroism
similar
observ
camelid
shark
vnar
show
wide
rang
melt
temperatur
valu
capabl
refold
follow
heat
denatur
excel
featur
convinc
vnar
potenti
develop
new
diagnost
reagent
rdt
vnar
also
demonstr
target
biomark
deriv
viral
diseas
ebola
hemorrhag
fever
ehv
ehv
deadli
viral
diseas
caus
ebola
viru
caus
agent
ehv
includ
bundibugyo
ebolaviru
sudan
ebolaviru
tai
forest
ebolaviru
zair
ebolaviru
goodchild
cowork
success
isol
two
vnar
immun
phage
display
librari
specif
nucleoprotein
ebola
viru
evalu
done
anderson
cowork
confirm
two
isol
vnar
excel
bind
affin
nucleoprotein
melt
temperatur
rel
low
therefor
employ
cdr
graft
techniqu
combin
site
direct
mutagenesi
improv
stabil
use
framework
vnar
shown
possess
good
thermost
two
deriv
vnar
construct
one
cdr
along
graft
onto
framework
anoth
cdr
graft
result
dyemelt
assay
show
excel
affin
low
melt
temperatur
wherea
higher
melt
temperatur
poor
affin
howev
three
amino
acid
differ
two
vnar
protein
six
singleand
doublepoint
mutant
cover
intermedi
two
clone
made
order
elucid
three
amino
acid
combin
respons
affin
stabil
found
singl
chang
amino
acid
offer
improv
melt
temperatur
maintain
affin
therefor
studi
suggest
contribut
antigen
bind
stabil
vnar
also
use
detect
variou
toxin
exampl
cholera
toxin
botulinum
toxin
bonta
complex
toxoid
ricin
staphylococc
enterotoxin
b
seb
cholera
acut
diarrheal
ill
caus
infect
small
intestin
vibrio
cholera
secret
cholera
toxin
reach
host
intestin
wall
cholera
toxin
chosen
studi
sever
pathogen
commerci
avail
liu
colleagu
demonstr
novel
anticholera
toxin
vnar
binder
specif
bound
solubl
antigen
isol
vnar
librari
studi
isol
vnar
binder
abl
display
slow
loss
antigen
bind
affin
h
incub
convent
antibodi
lost
antigen
bind
affin
short
period
time
henc
studi
reveal
vnar
capabl
bind
unacquaint
antigen
interest
zielonka
colleagu
recent
perform
rapid
isol
targetspecif
vnar
artifici
loop
three
distinct
diseas
target
name
epitheli
cell
adhes
molecul
epcam
ephrin
typea
receptor
human
serin
proteas
vnar
librari
bamboo
shark
chiloscyllium
plagiosum
use
yeast
display
techniqu
associ
subsequ
affin
matur
targetspecif
vnar
studi
rang
antigen
bind
vnar
select
screen
random
repertoir
three
antigen
state
due
inferior
bind
affin
sublibrari
undergon
affin
matur
random
region
respons
rapid
isol
targetspecif
vnar
result
epcamand
vnar
clone
isol
sublibrari
exhibit
greater
bind
affin
compar
clone
isol
initi
librari
outcom
work
prove
stepwis
affin
optim
first
random
accumul
low
affin
binder
follow
diversif
popul
enrich
variant
could
use
strategi
obtain
vnar
affin
low
nanomolar
rang
determin
thermost
epcambind
vnar
clone
isol
initi
librari
sublibrari
produc
solubl
protein
character
thermal
shift
assay
result
thermal
shift
assay
show
epcambind
vnar
clone
exhibit
high
tm
valu
rang
around
suggest
target
binder
high
affin
gener
vitro
without
undermin
thermost
vnar
scaffold
camachovillega
cowork
util
phage
display
technolog
isol
target
vnar
immun
horn
shark
heterodontu
francisci
recombin
human
tumour
necrosi
factor
alpha
proinflammatori
cytokin
predominantli
involv
diseas
rheumatoid
arthriti
psoriasi
accord
result
isol
vnar
clone
abil
identifi
neutral
vitro
therefor
vnar
therapeut
suggest
potenti
develop
immunotherapeut
drug
diseas
suppress
secret
proinflammatori
cytokin
bodi
hand
antiidiotyp
binder
proven
robust
tool
determin
pharmacokinet
studi
therapeut
antibodi
cancer
vaccin
develop
order
develop
specif
captur
ligand
colleagu
isol
antiidiotyp
vnar
recogn
therapeut
antibodi
cetuximab
matuzumab
semisynthet
librari
without
appli
neg
select
vnar
binder
show
high
specif
toward
cetuximab
matuzumab
success
isol
use
yeast
display
technolog
surprisingli
antiidiotyp
vnar
binder
isol
cross
react
either
cetuximab
matuzumab
therefor
combin
semisynthet
vnar
librari
yeast
surfac
display
would
promis
techniqu
rapid
isol
antiidiotyp
vnar
novel
approach
ideal
use
immunotherapeut
platform
develop
recent
cabanillasbern
cowork
success
isol
antivegf
vnar
potenti
inhibit
vitro
angiogenesi
studi
three
synthet
vnar
librari
construct
use
framework
without
cystein
one
cystein
two
cystein
residu
within
librari
use
select
six
mammalian
protein
aquaporin
vascular
endotheli
growth
factor
vegf
basic
fibroblast
growth
factor
leukemia
inhibitori
factor
lif
carcinoembryon
antigen
cea
glycophorin
gypa
least
one
vnar
found
antigen
clone
librari
without
cystein
select
antigen
isol
antivegf
vnar
undergon
threedimension
vitro
angiogenesi
assay
silico
analysi
result
vitro
angiogenesi
assay
suggest
vnar
capabl
inhibit
vitro
angiogenesi
wherea
result
silico
analysi
show
vnar
synthet
librari
could
rival
vnar
affin
matur
silico
model
vnar
promis
therapeut
candid
due
stabil
solubl
extraordinari
bind
loop
topolog
howev
inher
small
size
caus
vnar
short
serum
halflif
major
limit
tumourtarget
need
sinc
rapidli
clear
vivo
glomerular
filtrat
therefor
cowork
develop
vnarbas
halflif
extens
tool
increas
serum
circul
time
fusion
partner
studi
involv
nand
ctermin
fusion
vnar
antihuman
serum
albumin
hsa
vnar
isol
immun
spini
dogfish
squalu
acanthia
known
fusion
construct
shown
retain
high
bind
affin
hsa
comparison
unconjug
parent
domain
fusion
construct
exhibit
significantli
increas
vivo
halflif
addit
fusion
construct
display
capabl
enhanc
pharmacokinet
effect
mous
rat
monkey
therapeut
applic
human
nonhuman
immunoglobulin
scaffold
requir
minim
immunogen
enhanc
thermodynam
stabil
fold
express
properti
first
human
vnar
report
kovalenko
colleagu
isol
antihsa
vnar
clone
use
model
construct
number
human
variant
known
human
perform
convert
half
noncdr
residu
human
germlin
v
k
sequenc
result
human
molecul
larg
retain
specif
affin
antigen
bind
parent
vnar
crystal
structur
complex
hsa
show
human
variant
bound
manner
differ
steven
cowork
extend
work
employ
templat
isol
domain
enhanc
biophys
properti
reduc
antigen
mutagen
follow
refin
clone
via
offrat
select
screen
hsa
lead
clone
assess
tendenc
dimer
toler
nand
ctermin
fusion
stabil
affin
rel
antigen
human
dendrit
cell
assay
addit
function
clone
verifi
vivo
extens
serum
halflif
typic
drug
format
analys
clone
known
show
insignific
antigen
high
affin
high
stabil
mous
rat
hsa
attribut
combin
demonstr
function
rat
model
pharmacokinet
establish
clinic
candid
convent
antibodi
deriv
higher
mammal
wide
employ
immunodiagnost
reagent
due
specif
howev
limit
use
convent
antibodi
rdt
lead
misdiagnosi
report
elsewher
therefor
becom
import
extens
investig
new
binder
better
stabil
biolog
sourc
use
surfac
technolog
natur
heavychain
antibodi
deriv
shark
known
vnar
discov
recent
year
highlight
review
shark
vnar
superior
convent
antibodi
mani
aspect
one
exampl
capabl
vnar
access
cryptic
recess
epitop
usual
antigen
convent
antibodi
made
breakthrough
medic
research
addit
smaller
size
high
solubl
excel
thermost
advantag
properti
suggest
antibodi
appli
immunodiagnost
especi
countri
tropic
region
sinc
mani
new
find
discov
shark
vnar
continu
effort
research
allianc
may
allow
heavychain
antibodi
overcom
hindranc
face
correspond
diseas
treatment
therapeut
platform
